Drugmaker Hikma cuts generics sales forecast a third time

Published On 2017-11-13 04:00 GMT   |   Update On 2021-08-18 09:12 GMT



Hikma Pharmaceuticals Plc on Thursday lowered 2017 revenue guidance for its generics business for the third time.


The Jordan-based firm, which makes and markets branded and non-branded generic and injectable drugs, said it expected revenue of around $600 million and a core operating margin in the low single-digits from its generics business.


In August it had lowered its generics revenue guidance by $50 million to about $620 million, having slashed it to $670 million from an initial $800 million last November.


(Reporting by Justin George Varghese in Bengaluru; editing by Jason Neely)





Tags:    
Article Source : REUTERS

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News